DDS vs LEVI

DDS exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.31. However, the stock is significantly overvalued, trading at $595.20—nearly double its Graham Number ($305.57) and Intrinsic Value ($255.01). While profitability remains high with an ROE of 31.90%, the company is facing a growth stagnation with negative YoY revenue and earnings growth. The disconnect between strong fundamental health and poor valuation/growth metrics suggests a limited upside from current levels.

LEVI presents a compelling growth-at-a-reasonable-price (GARP) opportunity, anchored by a stable Piotroski F-Score of 4/9 and a current price ($22.30) that sits comfortably below its growth-based intrinsic value of $40.12. While the Graham Number suggests a lower defensive floor of $13.25, the company's exceptional ROE of 25.41% and strong earnings growth (32.6% YoY) justify a premium. Despite bearish insider sentiment and a weak technical trend, the fundamental trajectory is supported by consistent earnings beats and a P/E ratio significantly lower than the sector average.